responses

Tagvenue Launches Tagvenue PRO, Bringing AI to Help Venues Win More Bookings

Tagvenue has launched Tagvenue PRO, an AI-powered platform that simplifies venue management by automating lead responses, payment tracking, and performance…

1 week ago

Constellation Software Inc. Announces Release Date for Third Quarter Results

October 20, 2025 17:12 ET  | Source: Constellation Software Inc. TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc.…

2 weeks ago

Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer

Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients1 New findings from this investigational…

3 weeks ago

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100…

3 weeks ago

SOPHiA GENETICS Launches AI-Powered Digital Twins to Enhance Intelligent Decision-Making in Oncology

BOSTON and ROLLE, Switzerland, Oct. 16, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in AI-driven precision medicine, today announced…

3 weeks ago

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

September 20, 2025 11:00 ET  | Source: C4 Therapeutics, Inc. Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response…

2 months ago

Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody iSCIB1+

July 22, 2025 02:00 ET  | Source: Scancell Holdings Plc SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent…

4 months ago

Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of…

5 months ago

Indian Researchers Call for Balanced and Responsible Research Assessments: Springer Nature Survey Reveals Global Insights

NEW DELHI, June 11, 2025 /PRNewswire/ -- A global survey conducted by Springer Nature reveals that researchers in India are…

5 months ago

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma

Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable…

5 months ago